Optiscan Imaging's (ASX:OIL) shares should trade well today as it has executed an exclusive supply agreement with UK based MR Solutions for its second generation endomicroscopy system.
Optiscan is a leader in microscopic imaging, with patented technologies for high-powered microscopes to be miniaturised and used inside the body.
The technology enables imaging of up to 1000 times magnification, to instantly view cellular level details without the requirement to surgically remove tissue via biopsy.
MR Solutions is the leading developer and manufacturer of the world’s first range of commercial, cryogen free, benchtop magnetic resonance imaging systems.
The systems are specifically designed for mice and rat studies, molecular imaging, and multi-nuclear applications, boasting a cryogen-free superconducting magnet technology.
MR Solutions has a significant presence at all major trade shows in the field of pre-clinical imaging, with customers in China, Taiwan, Japan, Korea, Russia, Spain, France, Germany, Belgium, UK, USA and Canada.
Substantial opportunities exist within this market for Optiscan, both in terms of unit sales and the flow on benefits of translational research into the clinical arena.
In excess of 1,000 relevant institutions have been identified as high priority research sales targets, with promotional activity to commence immediately.
Capitalised at just $7 million, sales traction could give Optiscan increased market recognition.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.